Talk:Disappearing polymorph

Some links which either shouldn't be or have not yet been cited directly

Here are some links I've come across with useful information, but which probably shouldn't (or have not yet been) cited directly. I'll probably add to this list as I go.

• http://unenumerated.blogspot.com/2005/11/patent-goo-self-replicating-paxil.html
• https://www.reddit.com/r/chemistry/comments/1kwa4h/i_have_some_questions_about_crystals_if_anyone/

Yitz (talk) 23:09, 4 July 2022 (UTC)

Phenomenon is not pharma and was noted before

The phenomenon was noticed before the 1980s, before it occurred in the pharmaceutical industry. Companies in the US and/or UK were making large crystals of some phosphate salt for optical applications. At some point crystals of a new hydrate, more stable but never seen before, started forming in their vats; and from then on nobody could grow the old hydrate, because seeds for the new one seemed to be everywhere. Old crystals also started growing crystals of the new form on their facets, spoiling them.
By the way, this article reads as if it was mostly lifted from an article in some semi-technical pharmaceutical magazine or pharmaceutical thesis. But it is about a physio-chemical phenomenon, so it should include more material from the chemistry point of view.
Also the idea that the polymorph of a drug may have different pharma properties, or require re-certification, may have legal merit but is scientific nonsense, since polymorphism is strictly about the crystal arrangement in the solid state and the drug will enter the body and pathogen cells only as (very dilute) solution. Jorge Stolfi (talk) 14:34, 30 June 2024 (UTC)

While it is dilite in the blood stream it needs to be in the body in the therapitic window. Different polymorphs have different bioavaioability. This is because they are absorbed differently by th stomach and intestines. 2001:4060:C006:3F70:A45A:3E57:7EEB:F30 (talk) 20:56, 30 June 2024 (UTC)